US Broker Ratings

Enhabit, Inc. (EHAB) Stock Analysis: Exploring Growth Potential in the Healthcare Sector

Enhabit, Inc. (NYSE: EHAB) has carved a niche for itself in the healthcare sector by offering specialized home health and hospice services across the United States. With a market capitalization..

Akebia Therapeutics, Inc. (AKBA) Stock Analysis: A Biotech Play with Nearly 98% Upside Potential

For investors eyeing the healthcare sector, Akebia Therapeutics, Inc. (NASDAQ: AKBA) presents an intriguing opportunity. This Massachusetts-based biopharmaceutical company is focused on the development and commercialization of therapeutics for kidney-related..

Taysha Gene Therapies, Inc. (TSHA) Investor Outlook: Exploring a Potential 246% Upside

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is capturing investor attention with a compelling potential upside of 246.47%. This biotechnology firm, based in Dallas, Texas, operates within the healthcare sector and..

CeriBell, Inc. (CBLL) Stock Analysis: A Strong Buy with 59.84% Upside Potential

CeriBell, Inc. (NASDAQ: CBLL), a pioneering name in the medical devices sector, is positioned at the intersection of healthcare innovation and technological advancement. Specializing in transformative solutions for neurological diagnoses,..

Akso Health Group (AHG) Stock Analysis: Unpacking a 676% Revenue Surge in the Healthcare Sector

For investors seeking dynamic growth potential within the healthcare sector, Akso Health Group (NASDAQ: AHG) stands out with an impressive revenue growth figure of 676%. Headquartered in Qingdao, China, Akso..

Semler Scientific, Inc. (SMLR) Stock Analysis: Navigating Challenges with a Strategic Focus on Healthcare Innovation

Semler Scientific, Inc. (NASDAQ: SMLR) operates within the healthcare sector, specifically in the medical devices industry, where it focuses on providing technology solutions designed to enhance clinical effectiveness and efficiency...

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a Potential 258% Upside in Biotech

Anavex Life Sciences Corp. (NASDAQ: AVXL) is capturing the attention of investors with its promising potential for significant upside. As a clinical-stage biopharmaceutical company, Anavex specializes in developing therapeutics for..

AxoGen, Inc. (AXGN) Stock Analysis: Promising 131.96% Upside Potential with Strong Buy Ratings

Investors looking for opportunities in the healthcare sector might find AxoGen, Inc. (NASDAQ: AXGN) a compelling choice, especially with a potential upside of 131.96% and a unanimous buy rating from..

REGENXBIO Inc. (RGNX) Investor Outlook: Unpacking the 262% Upside Potential

REGENXBIO Inc. (NASDAQ: RGNX), a cutting-edge player in the biotechnology sector, presents a compelling investment narrative, especially for those drawn to high-risk, high-reward opportunities. With a focus on innovative gene..

Nuvation Bio Inc. (NUVB) Stock Analysis: Exploring a Potential 263.79% Upside in the Biotech Sector

Nuvation Bio Inc. (NASDAQ: NUVB), a clinical-stage biopharmaceutical company, has captured investor attention with a remarkable potential upside of 263.79%. As a player in the biotechnology sector, Nuvation Bio focuses..

AbCellera Biologics Inc. (ABCL) Stock Analysis: Exploring a 125% Upside Potential

AbCellera Biologics Inc. (NASDAQ: ABCL), a biotechnology company based in Vancouver, Canada, is fast capturing the attention of investors with its compelling market position and potential upside. With a market..

Ardelyx, Inc. (ARDX) Investor Outlook: Analyzing the 191% Potential Upside for Biotech Enthusiasts

Ardelyx, Inc. (NASDAQ: ARDX), a prominent player in the healthcare sector, specifically within the biotechnology industry, has been gaining attention for its promising drug pipeline and substantial growth potential. Headquartered..

Altimmune, Inc. (ALT) Stock Analysis: A 471% Upside Potential in the Biotech Arena

In the ever-volatile world of biotechnology investments, Altimmune, Inc. (NASDAQ: ALT) stands out with a stunning 471% potential upside, according to analysts. As a clinical-stage biopharmaceutical company, Altimmune is making..

Sana Biotechnology, Inc. (SANA) Stock Analysis: Unveiling a 225% Potential Upside for Investors

Sana Biotechnology, Inc. (NASDAQ: SANA), a promising player in the healthcare sector, is generating buzz among investors with its potential for substantial returns. With a market capitalization of approximately $647.34..

Evolus, Inc. (EOLS) Investor Outlook: Potential 153% Upside Amid Strong Buy Ratings

Evolus, Inc. (NASDAQ: EOLS), a burgeoning name in the healthcare sector’s specialty and generic drug manufacturing industry, presents a compelling opportunity for investors, driven by a robust market presence and..

Kura Oncology, Inc. (KURA): Investor Outlook on a Biotech Firm with a 348% Potential Upside

Investors with a keen eye on the healthcare sector often look for innovation-driven opportunities in biotechnology, and Kura Oncology, Inc. (NASDAQ: KURA) is a name that might pique their interest...

InnovAge Holding Corp. (INNV) Stock Analysis: Exploring a 26.90% Potential Upside

InnovAge Holding Corp. (INNV) captures attention in the healthcare sector with a focus on providing comprehensive care for seniors through its Program of All-Inclusive Care for the Elderly (PACE). Operating..

Avanos Medical, Inc. (AVNS) Stock Analysis: Navigating Challenges with Strategic Innovation in Medical Devices

Avanos Medical, Inc. (NYSE: AVNS), a notable player in the medical devices sector, is currently navigating a complex landscape characterized by market volatility and strategic innovation. As of the latest..

Beta Bionics, Inc. (BBNX): Analyst Consensus and Growth Potential Highlight a 57.14% Upside

Beta Bionics, Inc. (NASDAQ: BBNX) is capturing the attention of investors with its promising trajectory in the medical devices sector. Based in Irvine, California, this healthcare company is focused on..

Bicycle Therapeutics plc (BCYC) Stock Analysis: Exploring the 260.89% Potential Upside

Bicycle Therapeutics plc (NASDAQ: BCYC), a prominent player in the biotechnology sector, is capturing investor attention with its impressive potential upside of 260.89%. With its focus on developing novel therapeutics..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds